Immunological Disorders & Immunotherapy
ISSN: 2593-8509
OPEN ACCESS Freely available online
Opinion Article

Developments and Advances in Activation Immunotherapy

Nina Shah*

Department of Immunology, University of Valencia, Valencia, Spain

DESCRIPTION

Activation immunotherapies are a class of treatments that aim to stimulate the immune system to fight cancer or other diseases. Unlike traditional chemotherapy or radiation therapy, which directly target cancer cells, activation immunotherapies work by activating and enhancing the body's own immune system to recognize and attack cancer cells. This approach offers the potential for more targeted and specific treatments with fewer side effects.

One type of activation immunotherapy is immune checkpoint inhibitors, which block the action of proteins that suppress the immune system, allowing T cells to attack cancer cells more effectively. Pembrolizumab is a well-known immune checkpoint inhibitor that has been approved for the treatment of several types of cancer [1,2]. Another type is adoptive cell transfer therapy, which involves removing T cells from a patient's blood, genetically engineering them to express a Chimeric Antigen Receptor (CAR) that recognizes and targets cancer cells, and then infusing the modified T cells back into the patient's body.

Cancer vaccines are another type of activation immunotherapy that stimulates the immune system to recognize and attack cancer cells by presenting them with specific antigens [3,4]. Cytokine therapy uses cytokines to stimulate the immune system, and oncolytic virus therapy uses viruses that are engineered to selectively infect and kill cancer cells while leaving healthy cells unharmed. Antibody-based immunotherapy involves using monoclonal antibodies to target specific proteins on the surface of cancer cells.

Despite their potential, activation immunotherapies face challenges in identifying the right targets for therapy and managing side effects such as autoimmune reactions and inflammation. Combination therapies that use multiple types of activation immunotherapies may hold promise for improving treatment outcomes and reducing side effects [5].

Research in activation immunotherapy is advancing rapidly, and new biomarkers and delivery technologies are being developed to improve treatment efficacy and reduce side effects. With ongoing research and technological advances, activation immunotherapies hold significant promise for improving the lives of patients with cancer and other diseases [6].

Activation immunotherapies have revolutionized the way cancer and other diseases are treated, and they continue to be an active area of research and development. Here are some recent developments and advances in activation immunotherapy:

Personalized immunotherapy

Recent advances in genomics and immunology have enabled the development of personalized immunotherapy that targets the unique molecular and genetic characteristics of a patient's cancer cells. This approach involves sequencing the genome of a patient's tumor and identifying specific mutations or antigens that are unique to the tumor. Based on this information, personalized vaccines or adoptive cell transfer therapies can be designed to target these specific antigens, leading to more targeted and effective treatment [7].

Combination therapies: Combination therapies that use multiple types of activation immunotherapies have shown promise in improving treatment outcomes and reducing side effects. For example, combining immune checkpoint inhibitors with chemotherapy or radiation therapy has been shown to improve response rates and overall survival in patients with certain types of cancer.

Improved delivery technologies: Delivery technologies for activation immunotherapies are being developed to improve treatment efficacy and reduce side effects. For example, nanoparticle-based delivery systems can target specific cells or tissues, leading to more targeted and effective treatment.

Biomarkers for predicting response: Biomarkers are being developed to predict which patients are likely to respond to activation immunotherapy. For example, the presence of certain immune cell types or high levels of certain cytokines in a patient's blood may indicate a higher likelihood of response to immunotherapy [8].

Immunotherapy for other diseases: Activation immunotherapies are being explored for the treatment of other diseases beyond cancer, including autoimmune diseases, infectious diseases, and

Correspondence to: Nina Shah, Department of Immunology, University of Valencia, Valencia, Spain, E-mail: shahnina48@gmail.com

Received: 22-May-2023, Manuscript No. IDIT-23-24372; **Editor assigned:** 25-May-2023, PreQC No: IDIT-23-24372 (PQ); **Reviewed:** 09-Jun-2023, QC No. IDIT-23-24372; **Revised:** 16-Jun-2023, Manuscript No: IDIT-23-24372 (R); **Published:** 23-Jun-2023; 10.35248/2593-8509.23.8.149

Citation: Shah N (2023) Developments and Advances in Activation Immunotherapy. Immunol Disord Immunother. 8:149.

neurodegenerative diseases. For example, checkpoint inhibitors have shown promise in the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Overall, the future of activation immunotherapy looks promising, with ongoing research and development aimed at improving treatment efficacy and reducing side effects.

REFERENCES

1. Zheng Y, Yang Y, Zong X, Yao C, Wen L, He W, et al. Experimental study on the effect of curcumol on NLRP3 inflammasome in hepatic stellate cells. Lishizhen Med Mater Med Res.2021; 32(1):58-60.
2. Zheng Y, Wang J, Zhao T, Wang L, Wang J. Modulation of the VEGF/AKT/eNOS signaling pathway to regulate liver angiogenesis to explore the anti-hepatic fibrosis mechanism of curcumol. J Ethnopharmacol. 2021;280:114480.
3. Zheng Y, Wang J, Wang J, Jiang R, Zhao T. Gut microbiota combined with metabolomics reveal the mechanism of curcumol on liver fibrosis in mice. Biomed Pharmacother. 2022;152:113204.
4. Song J, Han X, Yao YL, Li YM, Zhang J, Shao DY, et al. Acanthoic acid suppresses lipin1/2 *via* TLR4 and IRAK4 signalling pathways in EtOH-and lipopolysaccharide-induced hepatic lipogenesis. J Pharm Pharmacol. 2018;70(3):393-403.
5. Li G, Lin J, Peng Y, Qin K, Wen L, Zhao T, et al. Curcumol may reverse early and advanced liver fibrogenesis through downregulating the uPA/uPAR pathway. Phytother Res. 2020;34(6):1421-1435.
6. Zheng Y, Zhao T, Wang J, Jiang R, Huang J, Li W, et al. Curcumol alleviates liver fibrosis through inducing autophagy and ferroptosis in hepatic stellate cells. FASEB J. 2022;36(12):e22665.
7. Krenkel O, Hundertmark J, Ritz TP, Weiskirchen R, Tacke F. Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis. Cells. 2019;8(5):503.
8. Nwosu ZC, Alborzinia H, Wölfl S, Dooley S, Liu Y. Evolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts. Front Physiol. 2016;7:191.